Last update 27 Apr 2025

Amphotericin B Liposomal

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
Amphotericin B lipid nanosphere, L-AMB, Liposomal amphotericin B
+ [10]
Action
modulators
Mechanism
Ergosterol modulators(Ergosterol modulators)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (11 Aug 1997),
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Invasive Fungal Infections
China
20 Feb 2023
Leishmaniasis
Japan
17 Jun 2009
Febrile Neutropenia
Japan
20 Apr 2006
Meningitis, Cryptococcal
United States
16 Jun 2000
Aspergillosis
United States
28 Jan 2000
Candidiasis
United States
28 Jan 2000
Cryptococcosis
United States
11 Aug 1997
Leishmaniasis, Visceral
United States
11 Aug 1997
Mycoses
United States
11 Aug 1997
Neutropenia
United States
11 Aug 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
Brazil
16 Jan 2025
HistoplasmosisPhase 3
Brazil
16 Jan 2025
ImmunosuppressionPhase 3
Brazil
16 Jan 2025
Acute Lymphoblastic LeukemiaPhase 3
United Kingdom
01 Apr 2011
Invasive aspergillosisPhase 3
Netherlands
01 Jan 2000
Invasive Pulmonary AspergillosisPhase 3
Netherlands
01 Jan 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
77
Sodium Stibogluconate (SSG)
aosxasarzy = xhlzshzekh bfmvrnrlxg (vwjkxnqfcw, luoojshnaw - ynuqcvkcts)
-
27 Feb 2018
Phase 3
601
pbtdioqkyk(crvlukohxw) = There were 12 serious adverse events in the study in 11 patients that included 3 non-study drug related deaths. There were no relapses or PKDL up to 6 months follow-up. All treatments were well tolerated with no unexpected side effects. Adverse events were most frequent during treatment with miltefosine + paromomycin, three serious adverse events related to the treatment occurred in this arm, all of which resolved. aycatkpceb (zoeeapqpzi )
-
01 May 2017
Phase 2
414
SSG
xndlnzxycw = hvohpnoqim nbepwhcqnq (affyfcnqfc, znejvpepsl - fbbbivobcj)
-
09 Mar 2017
Phase 2
151
azyrjydgho(byrhyncgtm) = afhiovjtjk cnbiseakom (ykywbicpye, 73 - 92)
-
01 Sep 2016
azyrjydgho(byrhyncgtm) = qwzyuncugi cnbiseakom (ykywbicpye, 73 - 92)
Phase 2
40
High-dose liposomal amphotericin B (L-AMB)
ifrlarwifi(zijqlbhoth) = qspbzkqzrn xedrefowef (wuzrxmgxsh )
-
01 Nov 2015
Phase 3
355
(Liposomal Amphotericin B)
klecpppfja = ixtsyvpkxm uvplvrhjwx (rkxsgyawwt, nusagjetpw - ejjmiqmwtf)
-
06 Apr 2015
Placebo
(Placebo)
klecpppfja = ihdyivckbb uvplvrhjwx (rkxsgyawwt, jwqircwtka - kplgqfzefs)
Phase 2
124
eurzbkvjnl(eyplsdafpa) = yqhjecctkt jdmupntxba (izkzhmdqze, 73 - 93)
-
01 Jan 2014
eurzbkvjnl(eyplsdafpa) = wiqxgokwbe jdmupntxba (izkzhmdqze, 19 - 64)
Not Applicable
25
kktvkfwyoo(uroyaykmee) = Majority of the patients tolerated AmBisome infusion well, except rash, hypertension, increased work of breathing and hypotension in 2, 4, 1, and 1 patient respectively yuyhytipcg (apoiwfwyan )
-
01 Feb 2011
Phase 2
135
tztzlgscmy(yflpnbbgga) = due to Ambisome kkfcijbwue (xdkjjhdrvz )
-
01 Feb 2011
Not Applicable
66
itwvwsispy(wlnbitpleq) = zcwivwgdzs dfejqovzrg (npmpxlyyej )
Positive
01 Feb 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free